BRAF in colorectal cancer

The Evolving Treatment Landscape in BRAF-V600E–Mutated ...

Between 8% and 12% of patients with metastatic colorectal cancer present with a BRAF-V600E mutation, which is associated with a poor response to ...

BRAF Mutation in Colorectal Cancer: An Update - PMC

Colorectal cancer (CRC) is still one of the deadliest cancer-related diseases. About 10% of CRC patients are characterized by a mutation in the B-Raf ...

BRAF Mutation Colon Cancer | Know Your Biomarker

BRAF mutations are present in approximately 10%-15% of colorectal cancers, 35% of melanomas, and more than 50% of thyroid papillary carcinomas.

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights

BRAF-mutated colorectal cancer: clinical and molecular insights. Francesco Caputo Francesco Caputo 1 Department of Oncology and Hematology, Division of ...

BRAF mutant colorectal cancer as a distinct subset of colorectal cancer

BRAF mutant cancers represent a distinct subset of CRC with its own clinical implications with regard to prognosis, treatments and emerging therapeutic ...

Current Therapeutic Strategies in BRAF-Mutant Metastatic ... - Frontiers

Around 8–12% of patients with advanced colon rectal cancer (CRC) present with BRAF alterations, in particular V600E mutation, which is ...

A Treatment Evolution Is Underway in BRAF V600E–Mutated mCRC

“CRC with a BRAF mutation is a more aggressive form of cancer that doesn't respond to standard chemotherapy. It is more common in women [older ...

BRAF-Mutated Advanced Colorectal Cancer - ASCO Publications

On the basis of recent clinical trials, current standard-of-care therapies for patients with BRAFV600E-mutated metastatic colorectal cancer ...

Real‐world treatment and outcomes of patients with metastatic ...

BRAF mutation occurs in 5%–10% of metastatic colorectal cancers (mCRCs). Patients with BRAF mutant mCRC exhibit a specific metastatic pattern ...

Targeted Drug Trio for Colorectal Cancer with BRAF Mutations - NCI

For people with colorectal cancer with BRAF mutations, a treatment regimen that consists of three targeted cancer drugs—encorafenib ...

Management of BRAF-mutant metastatic colorectal cancer: a review ...

Results. The current standard therapies for first-line treatment of BRAF-mutated mCRC are chemotherapy with bevacizumab as well as 5- ...

Molecular profiling of BRAF-V600E-mutant metastatic colorectal ...

BRAF-V600E mutations occur in approximately 10% of tumors in patients with mCRC and are associated with poor prognosis relative to wild-type ...

BRAF Mutation and Cancer | Johns Hopkins Medicine

Mutations in the BRAF gene can cause normal cells to become cancerous. BRAF mutations are most commonly found in melanomas, but can occur in other forms of ...

Review Management of BRAF-mutant metastatic colorectal cancer

The combination of BRAF and MEK inhibitors has been evaluated in patients with BRAF-mutated mCRC, resulting in a modest overall response rate (ORR) of 12% and a ...

BRAF mutant colorectal cancer: prognosis, treatment, and new ...

Conclusions. Despite its low prevalence (5%–8%), BRAF V600 CRC has been extensively studied due to the very poor prognosis. Although BRAF-mt is a negative ...

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated ...

The BRAF V600E mutation occurs in approximately 10% of patients with metastatic colorectal cancer, with recent estimates ranging from as low as ...

Updates in BRAF V600E-Mutated Metastatic Colorectal Cancer - EMJ

The BRAF V600E mutation occurs in 8–12% of patients with metastatic colorectal cancer (mCRC), and is characterised by an aggressive clinical course and poor ...

Targeting BRAF Mutation Positive Cancers: Melanoma, Lung and ...

BRAF mutation has been reported in approximately 10–15% of colorectal cancers. Data also supports presence of BRAF mutations as a poor prognostic factor, as ...

Colorectal Cancer and KRAS/BRAF - Medscape Reference

Approximately 30% to 50% of colorectal tumors are known to have a mutated (abnormal) KRAS gene, indicating that up to 50% of patients with ...

Treatment of patients with BRAF V600E -mutated metastatic ...

BRAFV600E mutation is detected in ∼4%-9% of metastatic colorectal cancers (mCRCs) and defines a molecular subgroup with high biological ...